This trial is testing whether a combination of drugs is an effective preparative regimen for people with multiple myeloma who are candidates for autologous stem cell transplantation. The combination being tested is busulfan and melphalan with carfilzomib. They will compare the results to historical controls of people treated with melphalan, busulfan and bortezomib.
- Multiple Myeloma
2 Primary · 10 Secondary · Reporting Duration: 3 years
Side Effects for
5 Treatment Groups
Carfilzomib IV at dose: 56 mg/m2
1 of 5
Carfilzomib IV at dose: 45 mg/m2
1 of 5
Carfilzomib IV at dose: 20 mg/m2
1 of 5
Carfilzomib IV at dose: 27 mg/m2
1 of 5
Carfilzomib IV at dose: 36 mg/m2
1 of 5
36 Total Participants · 5 Treatment Groups
Primary Treatment: Carfilzomib · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What medical conditions can be addressed through the use of Carfilzomib?
"Carfilzomib is widely used for allogeneic hematopoietic stem cell transplant and chronic myelogenous leukemia. Additionally, it may be prescribed to aid those suffering from amyloidosis, thrombocythemia, essential, refractory multiple myeloma." - Anonymous Online Contributor
To what extent is participation being sought for this medical investigation?
"Indeed, clinicaltrials.gov verifies that this trial is actively seeking volunteers for participation. With its initial launch on May 22nd 2019 and latest update on April 23rd 2021, the study currently needs 36 individuals to sign up from a single site." - Anonymous Online Contributor
Are there any openings available for potential participants in this scientific trial?
"Clinicaltrials.gov confirms that this medical trial is engaging participants, having been first posted on May 22nd 2019 and most recently edited on April 23rd 2021." - Anonymous Online Contributor
What are the objectives of this research endeavor?
"Amgen, the study sponsor for this trial, has reported that their primary outcome of interest will be assessed over a three-year period. This involves measuring 36 participants' tolerability and any adverse reactions through CTCAE v4.0. Additionally, secondary outcomes including Veno-occlusive disease grading levels by using CTCAE v4.0., urine tests to determine response rates in complete/very good partial/partial no stable disease patients, and blood tests assessing Progression Free Survival are also being monitored during the study's duration." - Anonymous Online Contributor